Healthcare >> Analyst Interviews >> December 13, 1999
Photodynamic Therapy : Samuel Gerszonowicz – Hcfp Brenner Securities
SAMUEL (GERSZON) GERSZONOWICZ is a Research Analyst and Director with
HCFP/Brenner Securities, where he specializes in the biopharmaceutical
industry. He covers biotechnology and pharmaceuticals with special
emphasis in the drug-device arena. Prior to joining the firm, Mr.
Gerszonowicz was associated with Johnson Research & Capital, as well as
with MacDougall, MacDougall and MacTier, Inc., where he served as
Corporate and Investment Financial Advisor. He has contributed his
expertise in business development, investment/corporate finance, and
informatics to management and stakeholders for more than 20 years. Mr.
Gerszonowicz holds a Bachelor's degree in Economics and Genetics from
the University of Alberta, Canada. He includes skiing, hiking,
archeology, philosophy, and jazz among his personal interests. Profile
TWST: Samuel, what is PhotoDynamic Therapy, and why do you refer to it
as third millennium TechnoScience?
Mr. Gerszonowicz: PhotoDynamic Therapy describes the technology and